BeOne Medicines (ONC) Reiterated at Market Outperform by Citizens on Phase 3 Results

July 1, 2026 4:41 AM

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $396.00 price target on BeOne Medicines (NASDAQ: ONC).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found